Monthly News Review of PharmaSources (February) - R&D
In R&D, Chipscreen chidamide Ⅲ test reaches preset indicators, the company plans to submit an application for the marketing of a new indication.
March 13, 2023
by Caicai/PharmaSources
Sinopharm announces that Paxlovid from Pfizer is Available in China
China National Pharmaceutical Group (Sinopharm) announced that Paxlovid from Pfizer is allowed to introduce in China. Here is the news from Pharma Sources.
March 1, 2023
by PharmaSources
China approves use of Pfizer’s COVID drug Paxlovid
It is not immediately clear if China is already in talks with Pfizer to procure the pill.
February 15, 2022
by ExpressPharma
Biohaven and Pfizer announce results of rimegepant trial for acute treatment of migraine
This is the fourth positive phase-III study of rimegepant for the acute treatment of migraine, and the first to be conducted in the Asia Pacific.
February 15, 2022
by ExpressPharma
Pfizer and BioNTech to extend rolling submission for Covid-19 vaccine
Pfizer and BioNTech are set to extend their rolling submission to the US Food and Drug Administration (FDA) for amending the emergency use authorization (EUA) of the Covid-19 vaccine to include children aged six months to four years.
February 15, 2022
by Pharmaceutical-Technology
CytoReason and Pfizer Extend Collaboration to Leverage Machine Learning in Drug Development
CytoReason announced the extension of its collaboration agreement with Pfizer.
February 15, 2022
by AmericanPharmaceuticalReview
Singapore receives its first batch of Pfizer’s Paxlovid pill for COVID-19 treatment
Singapore has received its first batch of Pfizer's oral COVID-19 treatment Paxlovid, after authorities last week said they had approved the tablet for COVID-19 in adults at risk for severe disease, reported CNA.
February 14, 2022
by FirstWordPharma
FDA Postpones Decision on Pfizer COVID Vaccine for Kids Under 5
The U.S. Food and Drug Administration announced Friday that it will postpone an advisory panel meeting that was slated...
February 11, 2022
by drugs.com
FDA Postpones Decision on Pfizer COVID-19 Vaccine for Under 5s
The U.S. Food and Drug Administration announced Friday that it will postpone an advisory panel meeting.
February 11, 2022
by drugs.com
Pfizer reports 92% operational growth in full-year 2021 revenues
The company provided full year 2022 guidance for revenues in the range of $98bn to $102bn.
February 10, 2022
by Pharmaceutical-Technology
Pfizer receives CHMP positive opinion for novel COVID-19 oral treatment
Pfizer Inc. (NYSE: PFE) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) issued a positive opinion recommending the conditional marketing authorization...
February 7, 2022
by WorldPharmaNews
EU drug regulator OKs Pfizer COVID pill for high-risk patients
The endorsement by EMA for a conditional approval, if followed as usual by the European Commission, allows EU member states to deploy the drug after the regulator gave guidance for its emergency use late last year.
January 29, 2022
by ExpressPharma